Skip to main content

and
  1. Article

    Open Access

    Automated synthesis of [18F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions

    The radiohybrid (rh) prostate-specific membrane antigen (PSMA)-targeted ligand [18F]Ga-rhPSMA-7 has previously been clinically assessed and demonstrated promising results for PET-imaging of prostate cancer. The l...

    Alexander Wurzer, Daniel Di Carlo, Michael Herz in EJNMMI Radiopharmacy and Chemistry (2021)

  2. Article

    Open Access

    First In-Human Medical Imaging with a PASylated 89Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer

    PASylation® offers the ability to systematically tune and optimize the pharmacokinetics of protein tracers for molecular imaging. Here we report the first clinical translation of a PASylated Fab fragment (89Zr∙Df...

    Antonia Richter, Karina Knorr, Martin Schlapschy in Nuclear Medicine and Molecular Imaging (2020)

  3. Article

    Open Access

    Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity

    Several radiolabeled prostate-specific membrane antigen (PSMA) inhibitors based on the lysine-urea-glutamate (KuE) motif as the pharmacophore proved to be suitable tools for PET/SPECT imaging of the PSMA expre...

    Martina Wirtz, Alexander Schmidt, Margret Schottelius, Stephanie Robu in EJNMMI Research (2018)

  4. Article

    Open Access

    Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007

    Due to its high and consistent expression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) represents an ideal target for molecular imaging and targeted therapy using highly specific rad...

    Stephanie Robu, Alexander Schmidt, Matthias Eiber, Margret Schottelius in EJNMMI Research (2018)